Bayer reported Phase 3 data showing its Factor XIa inhibitor asundexian reduced secondary ischemic stroke risk by about 26% without increasing major bleeding, positioning the oral anticoagulant as a potential next‑generation alternative for stroke prevention. The company presented detailed results that build on their earlier topline readout and tighten the commercial narrative for Factor XIa inhibitors competing with established anticoagulation therapies. Investigators and competitors — including Bristol Myers Squibb and Johnson & Johnson programs — will use the data to benchmark efficacy and safety. Factor XIa inhibition is a niche anticoagulation strategy aiming to lower thrombotic events while preserving haemostatic function; regulators will weigh the benefit‑risk in considering label expansions or approvals.